Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort


Published in: Journal of Clinical Pathology

Document Version: Peer reviewed version

Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2020 the authors.
This is an open access Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date: 03. Feb. 2021
Mutational Profiling in suspected Triple-Negative Essential Thrombocythaemia using Targeted Next-Generation Sequencing in a Real World Cohort.

O Michail¹, P McCallion¹, JE McGimpsey¹, A Hindley¹, G Greenfield¹, J Feerick¹, C Arnold¹, NCP Cross², RJG Cuthbert¹, MF McMullin¹,³, MA Catherwood¹

¹Clinical Haematology, Belfast City Hospital, BHSCT Belfast, Northern Ireland.
²Wessex Regional Genetics Laboratory, Salisbury, UK
³Centre for Medical Education (CME), Queen’s University Belfast, Northern Ireland.

Correspondence to:
Dr Mark Catherwood, Clinical Haematology, Belfast City Hospital, BHSCT Belfast, BT9 7AB. Northern Ireland.
Tel: 02895048008: FAX: 02895048007
e-mail: mark.catherwood@belfasttrust.hscni.net

Key words: myeloproliferative neoplasm, triple-negative, next generation sequencing.

Short Title: Next generation sequencing in TN-ET.
Essential Thrombocythaemia (ET) is driven by somatic mutations involving the JAK2, CALR and MPL genes. Approximately 10% of patients lack driver mutations and are referred as ‘triple-negative’ (TN-ET). The diagnosis of TN-ET, however, relies on bone marrow examination which is not always performed in routine practice, and thus in the real world setting there are a group of cases with suspected TN-MPN.

In this real world cohort, suspected TN-ET patients were initially re-screened for JAK2, CALR and MPL and then targeted next-generation sequencing (NGS) was applied.

The thirty-five suspected TN-ET patients had a median age at diagnosis of 43 years (range 16-79) and follow-up 10 years (range 2-28). Median platelet count was 758 x 10⁹ L⁻¹ (range 479-2903). Thrombosis prior to and following diagnosis was noted in 20% and 17% of patients. Six patients were JAK2V617F and 2 patients were CALR positive on repeat screening. NGS results showed that 24 of 27 patients harboured no mutations. Four mutations were noted in 3 patients.

There was no evidence of clonality for the majority of suspected TN-ET patients with targeted NGS analysis. Detection of driver mutations in those who were previously screened suggests that regular rescreening is required. This study also questions the diagnosis of TN-ET without the existence of a clonal marker.
Introduciton

Essential Thrombocythaemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN), characterized by clonal proliferation of the megakaryocytic lineage leading to thrombocytosis. The disease is complicated by thrombotic and haemorrhagic events, variable progression to myelofibrosis and rarely transformation to acute myeloid leukaemia.1 ET is driven by generally mutually-exclusive somatic driver mutations involving the JAK2, CALR and MPL genes with reported frequencies at 50-60%, 20-30% and 1-5% respectively.2 These mutations all induce constitutive activation of the JAK-STAT signalling pathway and its downstream effectors in a cytokine-independent manner leading to a myeloproliferative phenotype.

A small proportion of ET patients do not harbour any of the three common driver mutations and are referred to as ‘triple-negative’ (TN-ET). This cohort of patients accounts for 10-15% of ET diagnoses and appears to be a heterogeneous entity comprising of clonal and polyclonal diseases.3 Recent high-throughput sequencing studies, using targeted gene panels and whole-exome sequencing, have interrogated the genetic basis of TN-ET. These have identified mutations in genes involved in epigenetic regulation (TET2, DNMT3A, ASXL1, EZH2, IDH1 and IDH2), RNA splicing (SF3B1, SRSF2, U2AF1) and regulation of cytokine signalling (CBL). Although mutations in these genes are not restricted to MPNs, their presence in TN-ET cohort can be of diagnostic value, providing evidence of clonality.3

This study aimed to determine the molecular profile of suspected TN-ET patients using next-generation sequencing (NGS) and to identify potential clonal biomarkers. Clinical outcomes including thrombo-haemorrhagic complications, myelofibrosis-free and leukaemia-free survival were also documented.

Methods

A real world cohort of 35 patients were included with a diagnosis of ET between the years of 1989-2018 according to the WHO classification. A retrospective audit of diagnosis and outcomes was undertaken.
Data collection

Demographic characteristics (age and gender) and clinical information (year of diagnosis, cardiovascular risk factors, blood parameters, bone marrow morphology, treatment and clinical outcomes) were determined. Bone marrow biopsy material was only available in 25 of the 35 cases and was reviewed blinded by an independent haematologist. The remaining 10 cases did not have a bone marrow but were considered likely to have a diagnosis of ET because in the past in the real world setting patients with a persistent elevated platelet count and no other cause have had a diagnosis of ET.\textsuperscript{4} Suspected TN-ET patients were included after excluding JAK2\textsuperscript{V617F}, CALR exon 9 and MPL exon 10 mutations by conventional techniques (allelic specific PCR, DNA fragment analysis and Sanger sequencing, respectively).\textsuperscript{5,6}

Next Generation Sequencing

Genomic DNA was extracted from whole peripheral blood and retested for JAK2\textsuperscript{V617F}, CALR exon 9 and MPL exon 10 mutations by conventional techniques. NGS was performed using the Illumina MiSeqTM platform and the Trusight Myeloid gene panel. Sequence variants were called using Somatic Variant Caller (Illumina), with variant filtering using a custom Classification Tree within the Cartagenia BENCH\textsuperscript{®} software. Reporting required total read depth >100X for known variants and >300X for novel variants and allelic frequencies >5%.

RESULTS

Clinical characteristics and haematological values

Thirty-five suspected TN-ET patients, diagnosed between the years of 1989-2018, were included in the study. The median age at diagnosis was 43 years (range 16-79) and 83% were female (table 1). The median duration of clinical follow-up was 10 years (range 2-28). Full blood count parameters at presentation (prior to initiating treatment) are shown in table 1. Median platelet count at presentation was 758 x 10\textsuperscript{9}/l (range 479-2903). Cardiovascular risk factors and thrombo-haemorrhagic complications prior to and following diagnosis are depicted in table 1. Thrombosis prior to and following ET diagnosis was noted in 20% and 17% of patients respectively. No patients had any significant haemorrhage. In this retrospective selected group of patients, no patients progressed to myelofibrosis or acute myeloid leukaemia. One patient died from metastatic disease of unknown origin, unrelated to the
haematological condition, however the diagnosis of ET was made in this particular patient in 1989 with a BM consistent with ET. Twenty-one patients (60%) were on cytoreductive therapy and fourteen (40%) on antiplatelet therapy alone.

**Molecular Results**

As the median duration of clinical follow-up was 10 years all cases were rescreened for the canonical driver mutations by conventional approaches.\(^5,6\) Of interest, six patients were JAK2V617F positive and two patients were CALR positive on repeat screening. (table 2). Twenty-seven patients were subsequently sequenced with the Trusight Myeloid gene panel. Four mutations were detected in three patients (table 3) with the remaining 24 patients not harbouring any identifiable mutations.

Of the 24 patients without an identifiable mutation, sixteen had available bone marrow biopsies. When reviewed by an independent haematologist twelve cases failed to meet the morphological criteria for MPN. However, 4 patients remained with a diagnosis of suspected TN-ET without the presence of a clonal marker (figure 1, table 4).

**DISCUSSION**

In this real world cohort of cases, we investigated the mutational profiles and reviewed the bone marrow biopsies of 35 cases of suspected TN-ET with a median clinical follow up of 10 years. The detection of JAK2V617F and CALR mutations in 23% patients when rescreened implies that the use of sensitive screening tools for driver mutations should be encouraged in the diagnostic workup of these cases. The rescreening of JAK2V617F used a sensitive real-time quantitative PCR assay that likely contributed to the enhanced identification of JAK2 positive cases. Low allele burden JAK2 mutants have been well described in other series of TN-MPN’s but may also indicate clonal haematopoiesis of indeterminate potential.\(^3,7,8\) Sensitivity can be improved when using isolated granulocytes or platelets in comparison to whole blood.\(^9\) The use of NGS is further supported by the observation that atypical JAK2 and MPL mutations have been identified in series of TN-MPN.\(^10-12\) Our series prompted the histological review in cases with available material. Of 13 cases where no identifiable clonal marker was identified 4 patients showed morphological features of ET (figure 1, table 4).
Again these results imply that either the 4 cases had a polyclonal haematopoiesis and may be hereditary MPN disorders or the technical limitations of the assay prevented the discovery of a clonal marker. In this particular study we used the Illumina Trusight Myeloid gene panel which is limited to 54 genes and only exon 10 of the MLPL gene and exon 12/14 of JAK2 are included with the potential of missing rarer mutations.

We recognise certain limitations of this study, including the fact that all patients did not have BM trephines as required for a WHO diagnosis of ET. As this is a retrospective series of cases with a median follow up of 10 years all available cases (n=25) were assessed by an independent Haematologist. The difference of opinion between the original diagnosis and that on review highlights the difficulty of producing completely reproducible morphological assessments in the real world setting. In this setting, patients with a persistent elevated platelet count and no other cause have in the past, been labelled as ET without BM. Now that clonal abnormalities are detected a raised platelet and the detection of a clone may be sufficient to have a diagnosis of ET.

This real world series demonstrates that a sizable proportion of patients do not have a clonal disease which raises issues concerning the management where cytoreductive therapy may not be warranted.

**CONCLUSION**

We have found no genetic evidence for clonality in the majority of patients diagnosed with suspected “triple-negative” ET using targeted myeloid gene panel NGS. We propose rescreening for canonical driver mutations is indicated, in light of their detection upon repeat genotyping in this group of patients.

This study should encourage others to reconsider the diagnosis in a similar set of real world cases that exist within MPN clinics throughout the country.
Statements:

Acknowledgements: The authors acknowledge Dr Jyoti Nangalia, Wellcome Sanger Institute for helpful discussions.

Contributions: MAC and OM wrote the manuscript and prepared all figures. CA, NCPC, MFM, PMC, AH, JF, GG and JEM contributed to the writing of the manuscript.

Funding: N/A

Competing Interests: No competing interests to declare

Patient Consent: Not required

Provence and Peer review: Not commissioned; externally peer reviewed
References:


Figure legends:

Figure 1a.
Patient number 25.

BM trephine biopsy (*haematoxylin & eosin*)
Hypercellular bone marrow with multiple pleomorphic and hyperlobulated megakaryocytes

Fig. 1b Patient number 33.

BM trephine biopsy (*haematoxylin & eosin*)
Hypercellular marrow with a large hyperlobulated megakaryocyte and a second megakaryocyte abutting it.

Table legends:

Table 1. Clinical and biological characteristics in 35 patients with suspected triple-negative essential thrombocythaemia.
Haematological and clinical information was collected at diagnosis; information concerning thrombosis and haemorrhage included events after diagnosis. *Median (range).*

Table 2.
Clinical and biological characteristics at most recent follow in 9 patients with suspected triple-negative essential thrombocythaemia in which driver mutations were detected on rescreening.
Haematological and clinical information was collected at retesting; *Median (range), F/U median follow up, Hb-Haemoglobin, Plt-Platelets, Hct-Haematocrit %.* Patient 10 was diagnosed in 2003 and received hydroxyurea but was stopped due to the formation of a leg ulcer.

Table 3. Clinical and biological characteristics in 3 patients with suspected triple-negative essential thrombocythaemia found to have mutations with next generation sequencing.
Haematological and clinical information was collected at retesting; *Median (range), F/U median follow up, Hb-Haemoglobin, Plt-Platelets, Hct-Haematocrit %

Table 4. Clinical and biological characteristics in 4 patients with suspected triple-negative essential thrombocythaemia without evidence of a clonal marker and histological suggestive of essential thrombocythaemia.
Patient 27 was diagnosed as ET with a BM 3 years post presentation and by this stage progression seems to have occurred.

Haematological and clinical information was collected at retesting; *Median (range), F/U median follow up, Hb-Haemoglobin, Plt-Platelets, Hct-Haematocrit %.*

<table>
<thead>
<tr>
<th>Age at diagnosis (years)*</th>
<th>43 (16-79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M/F)</td>
<td>8/29</td>
</tr>
<tr>
<td>Haemoglobin (g/l)*</td>
<td>139 (96-164)</td>
</tr>
<tr>
<td>Haematocrit %*</td>
<td>40 (28-48)</td>
</tr>
<tr>
<td>Platelet count (x10^9/l)*</td>
<td>758 (479-2903)</td>
</tr>
<tr>
<td>Leucocyte count (x10^9/l)*</td>
<td>8.5 (4.2-17.2)</td>
</tr>
<tr>
<td>Neutrophil count (x10^9/l)*</td>
<td>5.4 (2.2-10.7)</td>
</tr>
</tbody>
</table>

**Cardiovascular Risk Factors**

<table>
<thead>
<tr>
<th>Hypertension, n (%)</th>
<th>14 (40%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperlipidaemia, n (%)</td>
<td>16 (46%)</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>6 (17%)</td>
</tr>
<tr>
<td>Diabetes Mellitus, n (%)</td>
<td>1 (2.8%)</td>
</tr>
</tbody>
</table>

**Thrombo-haemorrhagic Complications**

<table>
<thead>
<tr>
<th>Thrombosis prior to diagnosis, n (%)</th>
<th>7 (20%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis following diagnosis, n (%)</td>
<td>6 (17%)</td>
</tr>
<tr>
<td>Major Bleeding prior to diagnosis, n (%)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Major Bleeding following diagnosis, n (%)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Thrombosis prior to diagnosis, n (%)</td>
<td>7 (20%)</td>
</tr>
</tbody>
</table>

Table 1. Clinical and biological characteristics in 35 patients with suspected triple-negative essential thrombocythaemia
<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/Sex at diagnosis</th>
<th>Hb (g/l)</th>
<th>Hct %</th>
<th>Plt x10⁹/l</th>
<th>F/U</th>
<th>Trephine Review</th>
<th>Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M,60</td>
<td>15</td>
<td>0.43</td>
<td>391</td>
<td>13</td>
<td>Y</td>
<td>P JAK2V617F-9%</td>
</tr>
<tr>
<td>5</td>
<td>M,71</td>
<td>9.2</td>
<td>0.25</td>
<td>263</td>
<td>15</td>
<td>Y</td>
<td>P JAK2V617F-13%</td>
</tr>
<tr>
<td>6</td>
<td>F,69</td>
<td>13.9</td>
<td>0.42</td>
<td>620</td>
<td>12</td>
<td>Y</td>
<td>P JAK2V617F-8%</td>
</tr>
<tr>
<td>10</td>
<td>F,56</td>
<td>13</td>
<td>0.4</td>
<td>379</td>
<td>15</td>
<td>Y*</td>
<td>P JAK2V617F-4%</td>
</tr>
<tr>
<td>18</td>
<td>F,25</td>
<td>11.3</td>
<td>0.34</td>
<td>453</td>
<td>13</td>
<td>Y</td>
<td>P CALR pos</td>
</tr>
<tr>
<td>19</td>
<td>F,57</td>
<td>13.8</td>
<td>0.4</td>
<td>463</td>
<td>7</td>
<td>Y</td>
<td>P JAK2V617F-15%</td>
</tr>
<tr>
<td>26</td>
<td>F,33</td>
<td>15</td>
<td>11.7</td>
<td>700</td>
<td>8</td>
<td>N</td>
<td>N/A JAK2V617F-17%</td>
</tr>
<tr>
<td>34</td>
<td>59,F</td>
<td>14</td>
<td>0.4</td>
<td>514</td>
<td>2</td>
<td>N</td>
<td>N CALR pos</td>
</tr>
</tbody>
</table>

Table 2. Clinical and biological characteristics at most recent follow in 9 patients with suspected triple-negative essential thrombocythemia in which driver mutations were detected on rescreening.

*Patient 10 was diagnosed in 2003 and received hydroxyurea but was stopped due to the formation of a leg ulcer

| Patient | Age/Sex | Hb (g/l) | Hct % | Plt x10⁹/l | F/U | Trephine Review | Mutation/
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>79,F</td>
<td>14</td>
<td>0.41</td>
<td>520</td>
<td>3</td>
<td>P</td>
<td>MPL c.1544G&gt;T, p. (Trp515Leu)-8% ASXL1 c.2196_2223del, p.(Gln733Glyfs*2)-30%</td>
</tr>
<tr>
<td>12</td>
<td>69,F</td>
<td>11.8</td>
<td>0.36</td>
<td>287</td>
<td>14</td>
<td>P</td>
<td>TET2 c.5650A&gt;G, p.Thr1884Ala)-12%</td>
</tr>
<tr>
<td>31</td>
<td>42,F</td>
<td>12</td>
<td>0.36</td>
<td>352</td>
<td>12</td>
<td>P</td>
<td>CBL c.1259G&gt;A, p.(Arg420Gln)-24%</td>
</tr>
</tbody>
</table>

Table 3. Clinical and biological characteristics in 3 patients with suspected triple-negative essential thrombocythemia found to have mutations with next generation sequencing.
<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Age/Sex</th>
<th>Hb (g/l)</th>
<th>Hct %</th>
<th>Plt x10^9/l</th>
<th>F/U</th>
<th>Cytoreductive Treatment</th>
<th>Trephine at diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>75,F</td>
<td>12</td>
<td>0.37</td>
<td>615</td>
<td>2</td>
<td>Y</td>
<td>Increase in number of megakaryocytes with clustering and nuclear lobulation</td>
</tr>
<tr>
<td>27*</td>
<td>43,F</td>
<td>12</td>
<td>0.36</td>
<td>581</td>
<td>8</td>
<td>Y</td>
<td>Increased numbers of megakaryocytes. Pleomorphic in size with some large hyperlobated forms. Grade 2 Reticulin</td>
</tr>
<tr>
<td>30</td>
<td>70,M</td>
<td>11.8</td>
<td>0.33</td>
<td>517</td>
<td>3</td>
<td>Y</td>
<td>Normal to increased megakaryocytes. Predominance of large mature forms some with deeply lobulated nuclei</td>
</tr>
<tr>
<td>33</td>
<td>40,F</td>
<td>12.7</td>
<td>0.38</td>
<td>1018</td>
<td>3</td>
<td>N</td>
<td>Increased loosely, clustered and large megakaryocytes. Some megakaryocytes have abnormal nuclei. No fibrosis</td>
</tr>
</tbody>
</table>

Table 4. Clinical and biological characteristics in 4 patients with suspected triple-negative essential thrombocythaemia without evidence of a clonal marker and histological suggestive of essential thrombocythaemia.

*Patient 27 was diagnosed as ET with a BM 3 years post presentation and by this stage progression seems to have occurred.*